Evolent Health vs ICF International
EVH and ICFI side by side, both in management and public relations services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How EVH and ICFI compare
ICF International is the larger company, worth 2.6 times as much as Evolent Health ($1.5B against $554M).
Evolent Health grew revenue faster over the last twelve months (14.1% versus −5.2% for ICF International).
ICF International keeps more of each dollar of sales as profit, with a net margin of 5.3% compared with −21.7% at Evolent Health.
ICF International pays a dividend yielding 0.69%; Evolent Health does not pay one.
ICF International scores higher on the StockData Score (21 against 7 for Evolent Health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | EVH | ICFI |
|---|---|---|
| Size and price | ||
| Market cap | $554M | $1.5B |
| Share price | $4.90 | $81.26 |
| Change, 1 year | 10.1% | 3.1% |
| Change, 5 years | −83.0% | −22.7% |
| Beta (5Y) | 0.82 | 0.68 |
| Employees | 4,200 | 8,400 |
| StockData Score | ||
| Total score | 7 | 21 (better) |
| Valuation score | 3 | 6 (better) |
| Growth score | 3 (better) | 2 |
| Performance score | 0 | 4 (better) |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 4 (better) |
| Valuation | ||
| P/E | – | 15.3× |
| P/S | 0.2× (better) | 0.8× |
| P/B | 1.5× | 1.3× (better) |
| EV/EBITDA | – | 9.2× |
| P/FCF | – | 7.8× |
| PEG | – | 1.13 |
| FCF yield | – | 12.8% |
| Fair value | $6.93 | $129.52 |
| Margin of safety | 29.3% | 37.3% (better) |
| Growth | ||
| Revenue growth (TTM) | 14.1% (better) | −5.2% |
| Revenue growth, 5Y average | 15.2% (better) | 4.4% |
| Net income growth (TTM) | – | −2.4% |
| EPS growth (TTM) | – | 0.19% |
| EPS growth, 5Y average | – | 11.5% |
| Profitability | ||
| Gross margin | 15.0% | 37.3% (better) |
| Operating margin | −18.5% | 8.1% (better) |
| Net margin | −21.7% | 5.3% (better) |
| FCF margin | – | 10.2% |
| Return on equity | −83.6% | 9.1% (better) |
| Return on invested capital | −23.0% | 8.2% (better) |
| Financial health | ||
| Debt / equity | 2.60 | 0.34 (better) |
| Net debt / EBITDA | – | 1.86 |
| Interest coverage | −6.2× | 5.3× (better) |
| Current ratio | 1.26 | 1.40 (better) |
| Altman Z-score | −0.24 | 2.74 (better) |
| Piotroski F-score | 5 | 7 (better) |
| Dividends and buybacks | ||
| Dividend yield | – | 0.69% |
| Payout ratio | – | 10.6% |
| Years of dividend growth | – | 0 |
| Dividend growth, 5Y average | – | 0.00% |
| Buyback yield | – | 3.2% |
| Shareholder yield | 0.00% | 3.9% (better) |
| Ownership | ||
| Held by institutions | 99.3% | 102% |
| Held by insiders | 3.3% | 1.8% |
| Insider net buying, 12 months | −$329K (better) | −$1.4M |
| Short interest, % of float | 9.7% | 3.6% |
Go deeper
- EVH stock overview
- EVH income statement
- EVH valuation and score
- ICFI stock overview
- ICFI income statement
- ICFI valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.